A fractional-order mathematical model for lung cancer incorporating integrated therapeutic approaches.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
received:
29
04
2023
accepted:
15
07
2023
medline:
3
8
2023
pubmed:
2
8
2023
entrez:
1
8
2023
Statut:
epublish
Résumé
This paper addresses the dynamics of lung cancer by employing a fractional-order mathematical model that investigates the combined therapy of surgery and immunotherapy. The significance of this study lies in its exploration of the effects of surgery and immunotherapy on tumor growth rate and the immune response to cancer cells. To optimize the treatment dosage based on tumor response, a feedback control system is designed using control theory, and Pontryagin's Maximum Principle is utilized to derive the necessary conditions for optimality. The results reveal that the reproduction number [Formula: see text] is 2.6, indicating that a lung cancer cell would generate 2.6 new cancer cells during its lifetime. The reproduction coefficient [Formula: see text] is 0.22, signifying that cancer cells divide at a rate that is 0.22 times that of normal cells. The simulations demonstrate that the combined therapy approach yields significantly improved patient outcomes compared to either treatment alone. Furthermore, the analysis highlights the sensitivity of the steady-state solution to variations in [Formula: see text] (the rate of division of cancer stem cells) and [Formula: see text] (the rate of differentiation of cancer stem cells into progenitor cells). This research offers clinicians a valuable tool for developing personalized treatment plans for lung cancer patients, incorporating individual patient factors and tumor characteristics. The novelty of this work lies in its integration of surgery, immunotherapy, and control theory, extending beyond previous efforts in the literature.
Identifiants
pubmed: 37528101
doi: 10.1038/s41598-023-38814-2
pii: 10.1038/s41598-023-38814-2
pmc: PMC10394091
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
12426Informations de copyright
© 2023. The Author(s).
Références
Allergol Int. 2022 Apr;71(2):169-178
pubmed: 35101349
Mol Cancer. 2023 Feb 21;22(1):40
pubmed: 36810079
Expert Rev Anticancer Ther. 2023 Feb;23(2):187-198
pubmed: 36655635
Sci Rep. 2021 Aug 2;11(1):15622
pubmed: 34341390
Chaos. 2019 Aug;29(8):083127
pubmed: 31472488
J Clin Med. 2023 Feb 16;12(4):
pubmed: 36836096
Integr Cancer Ther. 2019 Jan-Dec;18:1534735419890020
pubmed: 31838881
Chaos Solitons Fractals. 2020 Dec;141:110286
pubmed: 32989346
Onco Targets Ther. 2023 Feb 15;16:99-108
pubmed: 36814961
Hepatology. 2022 Jun;75(6):1604-1626
pubmed: 35253934
J Appl Physiol (1985). 2023 Mar 1;134(3):692-702
pubmed: 36727633
Oncologist. 2007 Jun;12(6):690-712
pubmed: 17602059
Pathol Res Pract. 2023 Apr;244:154338
pubmed: 36905697
Chaos. 2021 Dec;31(12):123101
pubmed: 34972335
Int J Mol Sci. 2023 Feb 16;24(4):
pubmed: 36835382
Nat Rev Mol Cell Biol. 2022 Jan;23(1):74-88
pubmed: 34508254